Oral COVID-19 antivirals market set for growth
Lagevrio and Paxlovid are the only COVID-19 pills cleared for emergency use at present, but others are coming with developers racing to bring oral antivirals to this potentially lucrative market.
When the coronavirus pandemic struck in late 2019 the biopharmaceutical industry’s initial focus was on the development of vaccines to prevent SARS-CoV-2. Moderna, for example, began working on its jab – now called Spikevax – just after the publication of the viral genome sequence in February [i]. Similarly, Pfizer started clinical trials of its vaccine – since renamed Comirnaty in April [ii] in partnership with Biontech.
Work on vaccines continues – particularly since the detection of variants like Delta and Omicron. According to the latest WHO data [i]there are 137 vaccines in clinical trials with a further 194 being tested in animal studies.
However, a growing developers have also started working on drugs for people who test positive for the disease, with the overall aim being to reduce the number of severe cases.
Initially the focus was on antibody based therapies with the combination products bamlanivimab, etesevimab[ii] and casirivimab, and imdevimab[iii] being among the first to win approval.
However, the high cost of these products and need for intravenous administration render them “inaccessible to the public,” according to a recent study published in the Lancet[iv].
As a result the focus has shifted again to oral, solid dose antiviral medicines. And several have been authorised for emergency use in major markets. In the European Union for example, the EMA OKed Merck & Co’s Lagevrio [v] - which was developed with Ridgeback Biotherapeutics - and Pfizer’s Paxlovid [vi]in December.
Likewise, in the US the Food and Drug Administration (FDA) has granted both pills emergency use authorisation, specifying they be used to treat patients who test positive and deemed at high risk for progression to severe COVID-19.
In addition, the UK MHRA has already granted both the Merck & Co [vii]and [viii] Pfizer products full approval.
Market potential
Both of the drugs are expected to generate significant earnings. In October [ix]Merck & Co forecast that Lagevrio would generate $5 to $7 billion in revenue in 2022.
Similarly analysts predict [x]the Pfizer product will bring in $24 billion. If accurate this figure would represent a good investment given that Pfizer spent [xi]$3 billion develop both Paxlovid and Comirnaty.
And other developers may join Merck & Co and Pfizer in the oral COVID-19 market in the near future. For example, Shionogi & Co [xii]has a product candidate called S-217622 in clinical trials. Like Paxlovid, the product seeks to suppress the replication of SARS-CoV-2 by selectively inhibiting 3CL protease.
Swiss drug firm Roche and US partner Atea were [xiii]working on AT-527, which inhibits an enzyme called RNA-dependant RNApolymerase thereby halting viral replication. However, Roche [xiv]left the project after the drug failed to show efficacy in Phase II studies. Atea plans [xv]to continue development of the product.
Chinese drug firm Kintor Pharma [xvi]is developing a SARS-CoV-2 ACE2 and TMPRSS2 antagonist called proxalutamide.
In October[xvii], Enanta Pharmaceuticals reported that a compound EDP-235 demonstrated promising results in preclinical COVID-19 studies. More recently the firm confirmed [xviii]plans to begin first-in-human studies this year.
And, in December, Reuters [xix]reported that Swiss drug firm Novartis is working on an oral therapy for all coronaviruses, including SARS-CoV-2 and its variants.
Efficacy and potential resistance
How many of these candidates continue to progress and join Lagevrio and Paxlovid on the market remains to be seen. But some observers predict [xx]the ultimate fate of all successful oral COVID-19 antivirals will be as components of combination therapies.
Combination therapies are less likely to encounter viral resistance than mono therapies, particularly if the constituent active pharmaceutical ingredients (APIs) inhibit viral replication through different mechanisms.
And viruses like HIV [xxi]and Herpes [xxii]have already demonstrated the ability to become resistant to oral monotherapies. Whether SARS-CoV-2 or its circulating variants are likely to develop resistance to any of the oral antivirals is unclear, but regulators have already raised concerns.
According to a BMJ report [xxiii]in December, the US FDA advisory panel that recommended Lagevrio be granted the EUA also had questions about the drug’s impact on hospitalization.
Initially, in a press release [xxiv]Merck said Lagevrio reduced the risk of hospitalization by 50% - which was the figure cited by the UK MHRA when it approved the product. However when the firm presented final data [xxv]to the FDA panel it said the drug cut the hospitalization risk by 30%, which several panellists said was poorly explained.
The panellists also raised concerns about the finding that in a Phase II trial of the drug 72 structural nucleotide changes to the spike protein were found in viruses isolated from patients in the treatment arm, compared with just nine in the placebo arm.
[ii] https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis
[iii] https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
[v] https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19
[vi] https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts
[vii] https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra
[ix] https://www.fool.com/earnings/call-transcripts/2021/10/28/merck-co-mrk-q3-2021-earnings-call-transcript/
[xi] https://s28.q4cdn.com/781576035/files/doc_downloads/transcript/2021/12/PFE-USQ_Transcript_2021-12-17.pdf
[xiii] https://ir.ateapharma.com/news-releases/news-release-details/ateas-527-oral-antiviral-drug-candidate-reduces-viral
[xiv] https://www.reuters.com/business/healthcare-pharmaceuticals/atea-pharma-says-deal-develop-covid-19-pill-with-roche-terminated-2021-11-16/
[xv] https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-introduces-new-strategic-clinical
[xvii] https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-Presents-New-Data-for-EDP-235-its-Lead-Oral-Protease-Inhibitor-Designed-for-the-Treatment-of-COVID-19-at-the-ISIRVWHO-Virtual-Conference-2021/default.aspx
[xviii] https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Fourth-Quarter-and-Year-Ended-September-30-2021-with-Webcast-and-Conference-Call-Today-at-430-p.m.-ET/default.aspx
[xix] https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-working-pan-coronavirus-oral-treatment-ceo-says-2021-12-06/
[i] https://www.sec.gov/Archives/edgar/data/1682852/000119312520074867/d884510dex991.htm
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance